04th week of 2013 patent applcation highlights part 33 |
Patent application number | Title | Published |
20130022568 | SINGLE PHASE DEPILATORY COMPOSITION - A depilatory composition, and a method of using a depilatory composition, where the present invention is a depilatory composition comprising: (1) a film-forming polymer; (2) depilatory active ingredients; and (3) a solvent system, wherein the depilation composition forms a peelable film after drying. The depilation composition of the present invention uses a blend of fully and partially hydrolyzed poly(vinyl alcohol). | 2013-01-24 |
20130022569 | HYDROGELS - The invention provides hydrogels comprising bioactive-based poly(anhydride-ester)s (PAEs) and methods for use thereof. | 2013-01-24 |
20130022570 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS - The present invention provides a crosslinked amine and amide polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritis, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like. | 2013-01-24 |
20130022571 | METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 CYSTEINE MUTANTS - IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections. | 2013-01-24 |
20130022572 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 2013-01-24 |
20130022573 | MACROCYCLIC INHIBITORS OF FLAVIVIRIDAE VIRUSES - Provided are compounds of Formula I: | 2013-01-24 |
20130022574 | Avirulent Salmonella Gallinarum Variants and Pharmaceutical Composition Using the Same - The present invention relates to avirulent | 2013-01-24 |
20130022575 | SYSTEMS AND METHODS OF REPLACING INTESTINAL FLORA - The invention relates to one or more systems and methods for creating a mixture of cultures used to replace intestinal flora. Specifically, the invention relates to methods and systems of treating diseases including | 2013-01-24 |
20130022576 | COMPOSITIONS AND METHODS FOR REDUCING THE INCIDENCE OF EQUINE DIGESTIVE DISORDERS - The present invention encompasses compositions and methods of reducing the incidence of equine digestive disorders. | 2013-01-24 |
20130022577 | PROBIOTIC COMPOSITIONS USEFUL FOR TREATMENT OF BIPOLAR DISORDER - Compositions and methods for treatment or prophylaxis of a bipolar disorder disease state, in which the compositions include the bacilli (1) | 2013-01-24 |
20130022578 | METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS - Provided herein are methods and systems for interfering with viability of bacteria and related compounds and compositions. | 2013-01-24 |
20130022579 | BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against | 2013-01-24 |
20130022580 | PREPARATION AND USE OF MERISTEMATIC CELLS BELONGING TO THE DENDROBIUM PHALAENOPSIS, ANISELLIA, POLYRRHIZA, VANILLA, CATTLEYA AND VANDA GENERA WITH HIGH CONTENT OF PHENYLPROPANOIDS, HYDROSOLUBLE POLYSACCHARIDES AND EXTENSINS - The present invention relates to the preparation of plant cell cultures belonging to the | 2013-01-24 |
20130022581 | PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 2013-01-24 |
20130022582 | MULTIPOTENT NESTIN-POSITIVE CELLS - The present invention relates to the use of at least one isolated multipotent stem cell for maintaining haematopoiesis in vitro, in which said multipotent stem cell is preferably a mesenchymal stem cell or, more preferably, said mesenchymal stem cell is a mesenchymal stem cell capable of expressing the nestin protein. The present invention also relates to an isolated cell population of adult nestin-positive mesenchymal cells from a mammal, including humans, to the use thereof for producing a drug for maintaining haematopoiesis in a mammal, for the prevention and/or treatment of at least one disease associated with a malfunction in maintaining haematopoiesis in a mammal, and for maintaining and expanding adult haematopoietic stem cells of said mammal, including a human. Furthermore, the present invention also relates to a method for maintaining haematopoiesis in vitro or to a method for evaluating the haematopoietic capacity of a mammal. | 2013-01-24 |
20130022583 | Direct Conversion of Cells to Cells of Other Lineages - Methods, compositions and kits for producing functional neurons, astroctyes, oligodendrocytes and progenitor cells thereof are provided. These methods, compositions and kits find use in producing neurons, astrocytes, oligodendrocytes, and progenitor cells thereof for transplantation, for experimental evaluation, as a source of lineage- and cell-specific products, and the like, for example for use in treating human disorders of the CNS. Also provided are methods, compositions and kits for screening candidate agents for activity in converting cells into neuronal cells, astrocytes, oligodendrocytes, and progenitor cells thereof. | 2013-01-24 |
20130022584 | METHODS AND COMPOSITIONS FOR THE REPAIR AND/OR REGENERATION OF DAMAGED MYOCARDIUM USING CYTOKINES AND VARIANTS THEREOF - Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are disclosed and claimed. In addition, methods, compositions, and kits for forming coronary vasculature including the administration of cytokines, variants of cytokines, cardiac stem cells, or combinations thereof are described. In particular, administration of variants of hepatocyte growth factor, such as NK1, 1K1, and HP11, are useful for the repair and/or regeneration of damaged myocardium or formation of coronary vasculature. Methods of activating cardiac stem cells in vitro are also disclosed. | 2013-01-24 |
20130022585 | REGENERATION AND REPAIR OF NEURAL TISSUE USING POSTPARTUM-DERIVED CELLS - Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed. | 2013-01-24 |
20130022586 | PRODUCTION AND USE OF BACTERIAL HISTAMINE - A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions. | 2013-01-24 |
20130022587 | Cycloalkyl-Substituted Imidazole Derivative - A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R | 2013-01-24 |
20130022588 | Stable formulations of a hyaluronan-degrading enzyme related applications - Provided are compositions that are stable formulations of a hyaluronan-degrading enzyme or are stable co-formulations of a fast-acting insulin and a hyaluronan degrading enzyme, including a recombinant human PH20 (rHuPH20). | 2013-01-24 |
20130022589 | METHODS OF TREATING HUMAN PAPILLOMAVIRUS - Two RNases (ranpirnase and the second embodiment disclosed in U.S. Pat. No. 5,728,805) are tested against human papillomavirus infections. QRT-PCR assays indicate that the RNases have anti-viral activity against type 11 HPV. | 2013-01-24 |
20130022590 | Compositions Comprising Zinc Finger Domains and Uses Therefor - The present invention relates to compositions of matter comprising zinc finger domains that bind to single-stranded RNA and are useful for modifying gene expression such as by regulating processing of messenger RNA (mRNA) or non-coding RNA (ncRNA). The invention also relates to screening, diagnostic and therapeutic methods employing such compositions of matter. | 2013-01-24 |
20130022591 | Methods of Reducing or Inhibiting Toxic Effects Associated with a Bacterial Infection Using Alkaline Phosphatase - This invention relates generally to a therapeutic use of alkaline phosphatase to reduce or inhibit toxic effects associated with a bacterial infection in a subject. | 2013-01-24 |
20130022592 | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme - Provided are methods for continuous subcutaneous insulin infusion (CSII) that employ a hyaluronan-degrading enzyme, including a recombinant human PH20 (rHuPH20). The methods can be used to more consistently control blood glucose during the course of CSII. The methods can be used to treat subjects having diabetes or other insulin-associated disease or condition. | 2013-01-24 |
20130022593 | METHODS OF DIAGNOSING ENDOMETRIOSIS - The present invention provides biomarkers for the diagnosis and prognosis of endometriosis. Generally, the methods of this invention find use in diagnosing or for providing a prognosis for endometriosis by detecting the expression levels of biomarkers, which are differentially expressed (up- or down-regulated) in endometrial cells from a patient with endometriosis. Similarly, these markers can be used to diagnose reduced fertility in a patient with endometriosis or to provide a prognosis for a fertility trial in a patient suffering from endometriosis. The present invention also provides methods of identifying a compound for treating or preventing endometriosis. Finally, the present invention provides kits for the diagnosis or prognosis of endometriosis. | 2013-01-24 |
20130022594 | SELECTIVE FAK INHIBITORS - A compound of the formula (I): | 2013-01-24 |
20130022595 | VARIANTS OF HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES - The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1. | 2013-01-24 |
20130022596 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC USE IN CANCER PATIENTS - Disclosed herein are methods and compositions useful for identifying therapies likely to confer optimal clinical benefit for patients with cancer. | 2013-01-24 |
20130022597 | Antibodies Directed To GPNMB And Uses Thereof - The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies. | 2013-01-24 |
20130022598 | Dual Specific Immunotoxin for Brain Tumor Therapy - We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors. | 2013-01-24 |
20130022599 | METHOD OF TREATING FIBROPROLIFERATIVE DISORDERS - Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Exemplary zvegf4 antagonists include anti-zvegf4 antibodies, inhibitory polynucleotides, inhibitors of zvegf4 activation, and mitogenically inactive, receptor-binding variants of zvegf4. The materials and methods are useful in the treatment of, inter alia, fibroproliferative disorders of the kidney, liver, and bone. | 2013-01-24 |
20130022600 | PD-1 ANTIBODIES IN COMBINATION WITH A CYTOKINE-SECRETING CELL AND METHODS OF USE THEREOF - The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer. | 2013-01-24 |
20130022601 | TRIVALENT, BISPECIFIC ANTIBODIES - The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 2013-01-24 |
20130022602 | METHODS AND COMPOSITIONS TO MODULATE ANTIVIRAL AND IMMUNE ACTIVITY RESPONSES - The invention is directed to an improved method to manufacture virus for use in vaccine by culturing infected cells that have been modified to overexpress miR-144. The invention is also directed to manipulating the activity or level of miR-144 in subjects in order to modulate the antiviral and immune response systems. | 2013-01-24 |
20130022603 | ANTIBODY AGAINST SEROTYPE I LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 2013-01-24 |
20130022604 | ANTIBODY AGAINST SEROTYPE B LIPOPOLYSACCHARIDE OF PSEUDOMONAS AERUGINOSA - Provided is a novel antibody having an excellent antibacterial activity against | 2013-01-24 |
20130022605 | ANTAGONISTS AGAINST TNFR1 AND METHODS OF USE THEREFOR - The invention provides methods for treating inflammatory diseases (e.g., chronic inflammatory diseases) comprising administering an antagonist of Tumor Necrosis Factor Receptor 1. The invention also provides ligands that contain an immunoglobulin single variable domain (domain antibody, dAb) monomer that binds Tumor Necrosis Factor Receptor 1, and methods of using the ligands. Also provided are nucleic acids encoding the ligands, recombinant host cells and methods for preparing the ligands. | 2013-01-24 |
20130022606 | NEUTRALIZING PROLACTIN RECEPTOR ANTIBODIES AND THEIR THERAPEUTIC USE - The present invention is directed to the neutralizing prolactin receptor antibody 006-H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling. | 2013-01-24 |
20130022607 | MUCOSAL VASCULAR ADDRESSINS AND USES THEREOF - The present invention relates to isolated antibodies and antigen-binding fragments that selectively bind human MAdCAM. | 2013-01-24 |
20130022608 | FULL-LENGTH IgG IMMUNOGLOBULINS CAPABLE OF RECOGNIZING A HETEROSUBTYPE NEUTRALIZING EPITOPE ON THE HEMAGGLUTININ STEM REGION AND USES THEREOF - Monoclonal antibodies that are full-length IgG-isotype immunoglobulins and that are characterized by a high broad-range neutralizing activity against the influenza A virus and capable of recognizing a specific hemagglutinin epitope that is highly conserved among different influenza A virus subtypes are provided. Also provided are therapeutic, prophylactic and diagnostic uses of such immunoglobulins. | 2013-01-24 |
20130022609 | METHOD OF TREATING ANDROGEN INDEPENDENT PROSTATE CANCER - The present invention is directed to a method treating prostate cancer. The method comprises administering to a patient in need thereof at least one compound selected from N-methyl-Δ3,3′-dihydroindole-2,2′ diketone; N-1-(β-D-O-triacetyl-xylopranosyl)-Δ3,3′-dihydroindole-2,2′ diketone; and N-1-(β-D-O-triacetyl-xylopranosyl)-N′-methyl-Δ3,3′-dihydroindole-2,2′ diketone. Preferably the compound is in an amount sufficient to inhibit growth, invasion, and/or metastasis of prostate cancer cells. | 2013-01-24 |
20130022610 | METHODS OF DECREASING GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH DYSLIPIDEMIA - Methods for treating abnormal glycosylated hemoglobin (HbA1c) levels in a patient in need thereof, wherein the provided methods comprise administering to a patient in need a therapeutically effective amount of an Interleukin-1β modulator. Also, the invention provides compositions comprising at least one lipid modifying agent and an IL-1β modulator. | 2013-01-24 |
20130022611 | METHODS AND COMPOSITIONS FOR MODULATING HEPSIN ACTIVATION OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR - The invention provides methods and compositions for modulating hepsin activity and the uPA/plasmin pathway, in particular by regulating pro-uPA activation by hepsin. | 2013-01-24 |
20130022612 | METHODS AND COMPOSITIONS FOR MALARIA PROPHYLAXIS - A composition for preventing malaria infection including a steric inhibitor of circumsporozoite protein cleavage. A pharmaceutical composition for preventing malaria infection including a steric inhibitor and a pharmaceutical carrier. A method of malaria infection prophylaxis including the step of administering an effective amount of the composition of the present invention. A method of malaria prophylaxis by sterically inhibiting circumsporozoite protein processing or by directly inhibiting a protease of a sporozoite from binding to its target. Methods of preventing sporozoite cell invasion or preventing circumsporozoite processing through steric or direct inhibition. | 2013-01-24 |
20130022613 | WISE/SOST NUCLEIC ACID SEQUENCES AND AMINO ACID SEQUENCES - The present invention relates to nucleic acid sequences and amino acid sequences which influence bone deposition, the Wnt pathway, ocular development, tooth development, and may bind to LRP. The nucleic acid sequence and polypeptides include Wise and Sost as well as a family of molecules which express a cysteine knot polypeptide. Additionally, the present invention relates to various molecular tools derived from the nucleic acids and polypeptides including vectors, transfected host cells, monochronal antibodies, Fab fragments, and methods for impacting the pathways. | 2013-01-24 |
20130022614 | IgE ANTIBODIES FOR THE TREATMENT OF CANCER - The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA). | 2013-01-24 |
20130022615 | Compositions and Methods for Antibodies Targeting Complement Protein C5 - The present invention relates to antibodies targeting complement protein C5 and compositions and methods of use thereof. | 2013-01-24 |
20130022616 | Interleukin-31 Monoclonal Antibody - An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats. | 2013-01-24 |
20130022617 | COMPOSITIONS AND METHODS FOR TREATING TUMORS, FIBROSIS, AND PULMONARY ALVEOLAR PROTEINOSIS - The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2. | 2013-01-24 |
20130022618 | HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF - The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease. | 2013-01-24 |
20130022619 | METHODS AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSION - The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of viral infections. More particularly, the invention relates to the use of methods and compositions for the inhibition of human immunodeficiency virus (HIV) transmission. | 2013-01-24 |
20130022620 | ASSAYS AND METHODS PERTAINING TO PRE-AMYLOID INTERMEDIATES - The present invention relates to amyloidogenic peptides, polypeptides and proteins; and methods for screening to identify modulators of polypeptide self-aggregation into amyloids. The invention further relates to assays and methods using islet amyloid polypeptide (IAPP) as a component of a model system with which to screen for modulators of islet amyloid formation and accumulation. Also encompassed are modulators identified using the assays and methods described herein and compositions comprising same. The present invention also relates to methods and compositions for modulating amyloid formation and accumulation, thereby providing novel treatments for amyloidoses. In a particular aspect, methods and compositions are presented for inhibiting islet amyloid formation and accumulation, thereby providing novel treatments for diabetes. | 2013-01-24 |
20130022621 | ANTIBODY FORMULATION AND THERAPEUTIC REGIMENS - The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease. | 2013-01-24 |
20130022622 | COMPOUNDS FOR THE TREATMENT OF AUTISM - A compound which inhibits the importation of chloride into neurons and a compound which improve the outflow of chloride from neurons for the use in treatment of autism, a pharmaceutical composition for use in the treatment of autism including such compound and a pharmaceutically acceptable carrier are described. | 2013-01-24 |
20130022623 | ANTIBODIES THAT SPECIFICALLY BIND TO TIM3 - Provided herein are antibodies specific for TIM3 that can be used to detect cancer cells, in particular, cancer stem cells. The antibodies can also be used in therapeutic compositions for treating cancer and reducing inflammation. | 2013-01-24 |
20130022624 | ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND USES THEREOF - The present invention discloses humanized anti-epidermal growth factor receptor antibodies, which have favorable binding activity (the binding affinity being 5.09×10 | 2013-01-24 |
20130022625 | Stabilized Antibody-Containing Liquid Formulations - An objective of the present invention is to provide stable antibody-containing formulations which are suitable for subcutaneous administration and in which aggregation formation is suppressed during long-term storage. | 2013-01-24 |
20130022626 | LONG-ACTING HUMAN FOLLICLE-STIMULATING HORMONE FORMULATION USING IMMUNOGLOBULIN FRAGMENT - The present invention relates to a long-acting human follicle-stimulating hormone formulation having improved in vivo duration and stability, comprising a human follicle-stimulating hormone conjugate that is prepared by covalently linking human follicle-stimulating hormone with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting human follicle-stimulating hormone formulation of the present invention maintains in vivo activity of human follicle-stimulating hormone at a relatively high level and remarkably increases the serum half-life thereof. | 2013-01-24 |
20130022627 | Combination Therapy With Antibody-Drug Conjugates - Methods for the treatment of Hodgkin's lymphoma comprising administering both a chemotherapeutic regimen and an antibody-drug conjugate compound to a subject in need thereof are provided. | 2013-01-24 |
20130022628 | ACYL PSEUDOPEPTIDES WHICH CARRY A FUNCTIONALIZED AUXILIARY ARM - The present invention is directed in particular to dipeptide-like compounds derived from functionally substituted amino acids, having fatty acid chains bound thereto through amidification of the amine functional groups of said dipeptide-like compounds, one end portion of which bears an accessory functional side chain spacer, with the other end portion being an acid group either in neutral or charged state. | 2013-01-24 |
20130022629 | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof - Disclosed are an assay to identify modulators of the PD-1:PD-L pathway and PD-1:PD-L pathway modulators, e.g., compounds and pharmaceutical compositions thereof. Methods for treating diseases influenced by modulation of the PD-1:PD-L pathway such as, for example, autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, immune deficiency, and other immune system-related disorders, are also disclosed. | 2013-01-24 |
20130022630 | METHOD FOR TREATING AMYLOID DISEASE - The invention relates to methods for treating human amyloid disease by administration of modified Aβ peptide immunogens. | 2013-01-24 |
20130022631 | VACCINE FOR CHIKUNGUNYA VIRUS INFECTION - The present invention relates to vaccine formulation capable of eliciting protective immune response against Chikun-gunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikun-gunya virus in a stable formulation. Methods of propagation and purification of the virus are discussed. The inactivated virus formulation is non-infectious, immunogenic and elicits protective immune response in mammalian host. The immunogenic composition is formulated for in vivo administration to humans. The invention also discusses the strategy of developing a subunit vaccine using the recombinant viral proteins as antigens for immunization. The recombinant virus antigens that are potentially immunogenic can be used in diagnosing for the presence of the virus. | 2013-01-24 |
20130022632 | RECOMBINANT FELINE LEUKEMIA VIRUS VACCINE CONTAINING OPTIMIZED FELINE LEUKEMIA VIRUS ENVELOPE GENE - The present invention provides vectors that contain and express in vivo or in vitro FeLV antigens that elicit an immune response in animal or human against FeLV, compositions comprising said vectors and/or FeLV polypeptides, methods of vaccination against FeLV, and kits for use with such methods and compositions. | 2013-01-24 |
20130022633 | MENINGOCOCCAL fHBP POLYPEPTIDES - The factor H binding activity of meningococcal fHBP can be uncoupled from its bactericidal sensitivity. NMR studies have identified various amino acid residues involved in the fHBP/fH interaction and one or more of these residues is modified in a fHBP to reduce or eliminate its ability to bind to fH. | 2013-01-24 |
20130022634 | NEW COMPOSITION AND METHODS FOR TREATMENT OF AUTOIMMUNE AND ALLERGIC DISEASES - The present invention provides improved methods and compositions for treating and preventing autoimmune and allergic diseases. More specifically, the invention relates to new immunomodulating complexes that are fusion proteins comprising a mutant subunit of the A1-subunit of the cholera toxin (CTA1), a peptide capable of binding to a specific cellular receptor, and one or more epitopes associated with an autoimmune or allergic disease. In the mutant CTA1 subunit, the amino acids corresponding to the amino acid 7, arginine, and amino acid 187, cysteine, in the native CTA1 have been replaced. | 2013-01-24 |
20130022635 | Expression Modulator For Clock Gene Bmal - The present invention provides a substance which can modulate expression of a Bmal gene effectively and with a wide range of application. Provided is an expression modulator for the Bmal gene comprising, as an active ingredient, one or more selected from the group consisting of hinoki cypress extract, | 2013-01-24 |
20130022636 | Physical Mode of Action Pesticide - A physical mode of action pesticide for application on plants and in soils, and methods of manufacture and application, comprising an active ingredient in the form of a polymer in a concentration of less than 0.1% wt., a surfactant, a co-solvent and a diluent in a hydrocolloid suspension. The suspension polymer is preferably a polysaccharide having a molecular weight of 10,000 to 25,000,000, and preferably in the range of about 600,000. The pesticide preferably also includes a targeting ingredient for directing the active ingredient to a particular target. | 2013-01-24 |
20130022637 | RECOMBINANT BACULOVIRUS VACCINE - The present invention provides a novel transfer vector and a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient, which are useful as preventive or therapeutic drugs for infectious diseases such as malaria and influenza; and methods for preventing and treating infectious diseases such as malaria and influenza. More specifically, the invention provides a recombinant transfer vector capable of expressing a foreign gene fused to a virus gene under the control of a dual promoter; a recombinant baculovirus; methods for the production thereof; pharmaceuticals containing the recombinant baculovirus as an active ingredient; and methods for preventing and treating infectious diseases such as malaria and influenza comprising administrating the recombinant baculovirus to patients. | 2013-01-24 |
20130022638 | Tuberculosis Vaccine - The present invention relates to an isolated microorganism belonging to the genus | 2013-01-24 |
20130022639 | EXPRESSION OF MENINGOCOCCAL FHBP POLYPEPTIDES - The meningococcal fhbp gene (encoding factor H binding protein) is naturally expressed from two independent transcripts by two differentially regulated promoters. In one transcript it is co-expressed with the neighbouring upstream gene from the P | 2013-01-24 |
20130022640 | IMMUNE MODULATORS RELATING TO FOXO3A - The invention provides methods of enhancing an immune response to a cancer antigen in a mammal comprising inhibiting the activity of the foxo3a gene or gene product in dendritic cells in the mammal. The invention also provides methods of suppressing an immune response to an autoimmune disease antigen in a mammal comprising increasing the activity of the foxo3a gene or gene product in dendritic cells in the mammal. The invention also provides related methods of treating cancer and autoimmune diseases. | 2013-01-24 |
20130022641 | Anti-Tumor Agent and Immunostimulating Agent - To provide a pharmaceutical composition comprising a ceramide-related substance having little adverse side effects as an active ingredient by using a raw material that is highly safe to a human body and is inexpensive. A pharmaceutical composition comprising at least one sphingoglycolipid derivative that is produced from a beer waste and is represented by the formula below as an active ingredient: wherein R3 represents H or OH; R4 is as defined by (a) or (b) (a) when R3 is H, R4 represents (CH2)13CH3 or (CH2)6CH═CHCH2CH═CH(CH2)4CH3; and (b) when R3 is OH, R4 represents (CH2)yCH3 (where Y represents an integer of 13 to 21) or (CH2)Z1CH═CH(CH2)Z2CH3 (where Z1 and Z2 independently represent 0 or a natural number, provided that Z1+Z2=19). | 2013-01-24 |
20130022642 | Dual Antagonist for TNF-A and IL-21 for Preventing and Treating Autoimmune Diseases - The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease. | 2013-01-24 |
20130022643 | Antimicrobial Anti-chafing Chelated Silver Oxide Compound - Described herewithin is a composition comprising an anti-chafing balm with C18-36 acid triglycerides, capric/carprylic triglycerides, and tribehinin together with a chelated silver oxide complex comprising a barrier film when applied to the skin. The film is a dual purpose antibacterial and anti-chafing barrier topically applied to human skin, providing a layer of chelated silver oxide complex further comprised of a dermatologically acceptable carrier, with friction (chafe) reducing properties, selected from the group consisting of organic solutions, gels, liquids, balms, aerosols, emulsifiers, lotions, water-in-oil emulsions, oil-in-water emulsions, surfactants, aloe barbedensis leaf juice and tocopherol acetate. | 2013-01-24 |
20130022644 | NOVEL N-PHENYLACETAMIDE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - Compounds of general Formula (I), | 2013-01-24 |
20130022645 | PHARMACEUTICAL FORMULATIONS OF BISPHOSPHONATE WITH ENHANCED ORAL BIOAVAILABILITY - Disclosed is an oral bisphosphonate formulation characterized by an enhanced clinical bioavailability of bisphosphonate and by the use of phytic acid and a delayed release means for releasing bisphosphonate at a site of the lower gastrointestinal tract. Having a low phytic acid content, the oral bisphosphonate formulation guarantees high safety to the patient. Moreover, the oral formulation is designed to allow the patients to take the medicament, together with food intake, at a bioavailability as high as that of an empty stomach, thus improving the convenience of drug administration for the patient. Therefore, the oral formulation is expected to provide higher therapeutic effects for osteoporosis. | 2013-01-24 |
20130022647 | POLYMERS FOR REVERSING HEPARIN-BASED ANTICOAGULATION - Embodiments presented herein relate to various polymers. Some of the polymer embodiments are heparin binding polymers. Some embodiments of the heparin binding polymers can be employed to bind to heparin for methods such as separating, purifying, removing, and/or isolating heparin and heparin like molecules. | 2013-01-24 |
20130022648 | GRANULES OF POROUS BIOCOMPATIBLE MATERIALS - The disclosure provides granular forms of porous biomaterials and methods for forming and applying these biomaterials, including uses to promote vascularization and tissue ingrowth. | 2013-01-24 |
20130022649 | SNALP FORMULATIONS CONTAINING ANTIOXIDANTS - The present invention provides methods of preventing, decreasing, or inhibiting the degradation of cationic lipids and/or active agents (e.g., therapeutic nucleic acids) present in lipid particles, compositions comprising lipid particles stabilized by these methods, methods of making these lipid particles, and methods of delivering and/or administering these lipid particles, e.g., for the treatment of a disease or disorder. | 2013-01-24 |
20130022650 | COMPOSITIONS CONTAINING SALMETEROL, FLUTICASONE AND CROMOGLICIC ACID - The present invention relates to the use of cromoglicic acid and/or nedocromil salts in pharmaceutically effective amounts in a pharmaceutical composition containing salmeterol or a pharmaceutically acceptable salt thereof as a | 2013-01-24 |
20130022651 | HYDROGEL MATERIALS INCORPORATING ELUTING CERAGENIN COMPOUND - A hydrogel polymer includes a ceragenin compound. The ceragenin compound has a hydrophobicity/hydrophilicity that produces a release rate in a range of 0.1-100 μg/ml for at least 3 days. | 2013-01-24 |
20130022652 | STABLE MEDICATED CHEWING GUM COMPRISING CYCLODEXTRIN INCLUSION COMPLEX - The present invention provides stable medicament-containing chewing gum compositions comprising an inclusion complex comprising cyclodextrin and one or more active compound(s) according to formula I, such as cetirizine, and methods for preparing such chewing gum. | 2013-01-24 |
20130022653 | BIOMIMETIC HYDROXYAPATITE SYNTHESIS - A method for preparing nanoscale hydroxyapatite particles by combining an amount of a calcium ion source, which includes calcium acetate, and an amount of a phosphate ion source, wherein the amounts are sufficient to produce nanoscale hydroxyapatite particles and the amounts are combined under ambient conditions to produce the hydroxyapatite particles. Nanoscale hydroxyapatite particles are also presented. | 2013-01-24 |
20130022654 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF TAPENTADOL - A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean T | 2013-01-24 |
20130022655 | Metal Oxide Nanocomposites for UV Protection - The present invention relates to a method of protecting a substrate against ultraviolet (UV) irradiation by applying to the substrate metal oxide nanocomposite particles showing at the same time high transmittance of visible light and high absorbance of UV light. | 2013-01-24 |
20130022656 | WATER CONTAINING POWDER COMPOSITION - Powdery composition comprising: a) at least one powder in form of core-shell particles, the core comprising liquid water or a liquid aqueous phase and the shell comprising hydrophobic or hydrophobized particles and b) at least one powder comprising carrier and b1) at least partially water soluble liquid and/or b2) a water reactive substrate each located in and/or on the carrier. Process for the manufacture of a creamy composition from the powdery composition according to claim | 2013-01-24 |
20130022657 | EMBEDDED BIOCIDE - A phosphonium compound embedded in a matrix substrate wherein the phosphonium compound is selected from a group consisting of tris (hydroxyorgano) phosphine (THP), a THP | 2013-01-24 |
20130022658 | DEPOSITING MATERIAL WITH ANTIMICROBIAL PROPERTIES ON PERMEABLE SUBSTRATE USING ATOMIC LAYER DEPOSITION - Embodiments relate to depositing a layer of antimicrobial material such as silver on a permeable substrate using atomic layer deposition (ALD). A deposition device includes two injectors that inject source precursor, reactant precursor, purge gas or a combination thereof onto the permeable substrate that passes between the injectors. Part of the gas injected by an injector penetrates the permeable substrate and is discharged by the other injector. The remaining gas injected by the injector moves in parallel to the surface of the permeable substrate and is discharged via an exhaust portion formed on the same injector. While penetrating the substrate or moving in parallel to the surface, the source precursor or the reactant precursor becomes absorbed on the substrate or react with precursor already present on the substrate to deposit the antimicrobial material on the substrate. | 2013-01-24 |
20130022659 | Band, bracelet or strip carrier for an anti-microbial agent to reduce the spread of disease - A band, bracelet, strip or patch to be worn around the wrist or ankle or removably attached to the back of the wearer's hand. Each article is treated with an anti-microbial agent (e.g., tea tree oil) that is capable of killing germs and potentially harmful bacteria. The band, bracelet, strip or patch is impregnated with the anti-microbial agent during manufacture or saturated with the agent by the wearer following manufacture. The agent is delivered to the skin (e.g., the hands) of the wearer by way of either dispersion (exudation) and migration (mixed with the wearer's normal body oil) or by direct touch contact with and transmission to the wearer's fingers so as to reduce the spread of illness and disease. | 2013-01-24 |
20130022660 | DRUG DELIVERY SYSTEM FOR THE PREVENTION OF CEREBRAL VASOSPASM - The present invention relates to the treatment and prevention of vasospasm. The present invention provides a system for treating a cerebral vasospasm in a human utilizing a pharmaceutical composition and administrating a therapeutically effective amount of the pharmaceutical composition to a predetermined location in close proximity to a cerebral artery within a subarachnoid space wherein the pharmaceutical composition produces a localized pharmacologic effect thereby treating the cerebral vasospasm. | 2013-01-24 |
20130022661 | BIO-REMODABLE BONE AUGMENTATION DEVICE AND METHOD - A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having structural properties so as to aid in the generation of new bone tissue and eventually be reabsorbed in the newly formed bone tissue. This structural and bio-remodable implant reduces, if not eliminates, the need to remove the implantable member from the patient once new bone tissue is formed. A kit including the implantable devices and bone growth material is disclosed. Methods of use are also disclosed. | 2013-01-24 |
20130022662 | COMPRESSED CHEWING GUM TABLET COMPRISING TASTE-MASKING AGENT - The present invention relates to compressed chewing gum tablets comprising a useful antihistamine. In particular, the present invention is directed to compressed chewing gum tablet, which effectively mask the unpleasant tastes of compound according to formula I, such as cetirizine, contained therein and methods for preparing such compressed chewing gum tablet. | 2013-01-24 |
20130022663 | Method of making and using a topical medicated formula and delivery system to use to prevent and treat breast diseases and breast cancer as well as use as skin wellness and anti-wrinkle formula - Breast cancer and breast disease are common in women and becoming more frequent in men. Early treatment is vital for better outcomes. This formula consists of a liquid anti-disease topical and/or intraductal anti-breast-disease and anti-cancer—including against precursors to cancer and atypical cells—formula that can be delivered to the source where breast cancer begins by use of a number of bio-available components and multiple diffusion and delivery systems, preventing and/or treating maladies that include, but are not limited to degenerative diseases and accumulation of toxins in the breast tissue. | 2013-01-24 |
20130022664 | E.COLI LPFA ANTIGEN FOR PREVENTION AND TREATMENT OF INFECTIOUS DISEASES - The present disclosure relates to methods and compositions for the treatment and prevention of microbial infections and for the enhancement of resistance to infection. The disclosure includes administration of an effective amount of an | 2013-01-24 |
20130022665 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS - Here described are compounds of formula I: | 2013-01-24 |
20130022666 | METHODS AND COMPOSITIONS FOR TRANSFER OF MITOCHONDRIA INTO MAMMALIAN CELLS - Disclosed are compositions comprising a lipid carrier and a mitochondria. Also disclosed are methods of delivering exogenous mitochondria to a cell and methods of treating or reversing progression of a disorder associated mitochondrial dysfunction in a mammalian subject in need thereof | 2013-01-24 |
20130022667 | FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE WOUND HEALING - Methods of treating a wound in a subject are provided comprising administering to the subject an amount of an inhibitor of Fidgetin-like 2. Compositions and pharmaceutical compositions comprising an amount of an inhibitor of Fidgetin-like 2 are also provided. Methods are also provided for identifying an inhibitor of Fidgetin-like 2. | 2013-01-24 |
20130022668 | Biologically Active Taxane Analogs And Methods Of Treatment By Oral Administration - The present invention relates to a novel chemical compound of formula S-(1): | 2013-01-24 |